EECP is FDA-cleared for cardiac disease, but decades of clinical use and published research have demonstrated benefit across a much wider range of conditions. Each page below summarizes the peer-reviewed evidence and links to providers who treat that condition.
This library summarizes published clinical research. It is not medical advice.
EECP enhances microvascular density, boosts nitric oxide production, and improves cellular oxygen delivery — the same mechanisms targeted by leading longevity protocols.
Elite athletes use EECP to accelerate recovery, increase VO₂ max, and build collateral circulation — legally and without drugs.
By reducing systemic inflammation and improving microvascular perfusion, EECP addresses the vascular component of autoimmune conditions including lupus, rheumatoid arthritis, and Sjögren's.
CKD is fundamentally a vascular disease of the kidneys. EECP improves renal perfusion and has shown improvements in GFR in early-stage CKD patients.
Chronic wounds — diabetic foot ulcers, venous leg ulcers, pressure injuries — fail to heal because of impaired microvascular blood flow. EECP restores that flow.
Vascular dementia and Alzheimer's share a common feature: impaired cerebral blood flow. EECP increases cerebral perfusion and has shown improvements in cognitive function scores.
Diabetes damages blood vessels throughout the body. EECP addresses the downstream consequences — neuropathy, retinopathy, nephropathy, and cardiovascular risk — by restoring microvascular function.
Up to 80% of erectile dysfunction is vascular in origin. EECP increases pelvic blood flow, stimulates nitric oxide production, and has shown improvements in IIEF scores in every clinical trial conducted.
Fibromyalgia involves central sensitization and impaired microvascular perfusion to muscles. EECP improves tissue oxygenation and reduces pain scores in fibromyalgia patients.
EECP reduces systolic and diastolic blood pressure by improving endothelial function, increasing nitric oxide, and reducing vascular resistance — effects that persist for months after treatment.
Long COVID is increasingly understood as a vascular and microvascular disease. EECP addresses the endothelial dysfunction and impaired perfusion that drive persistent symptoms.
EECP improves pulmonary circulation and right heart function in COPD and pulmonary hypertension, reducing breathlessness and improving exercise tolerance.
Mycotoxin exposure causes systemic inflammation and vascular dysfunction. EECP supports detoxification by improving lymphatic and vascular circulation and reducing inflammatory burden.
Peripheral neuropathy — whether diabetic, idiopathic, or chemotherapy-induced — is driven by impaired blood flow to nerves. EECP restores that flow and has shown improvements in nerve conduction.
PAD is caused by arterial narrowing in the legs. EECP stimulates collateral vessel formation and improves ankle-brachial index — reducing claudication and improving walking distance.
Cerebrovascular dysfunction contributes to Parkinson's progression. EECP improves cerebral blood flow and has shown improvements in motor function and quality of life in Parkinson's patients.
Raynaud's is caused by vasospasm and impaired peripheral circulation. EECP improves endothelial function and nitric oxide production, reducing the frequency and severity of attacks.
RLS is associated with impaired dopaminergic signaling and peripheral vascular dysfunction. EECP improves peripheral circulation and has shown reductions in RLS symptom severity.
Diabetic and hypertensive retinopathy are caused by microvascular damage to the retina. EECP improves retinal perfusion and has shown improvements in visual acuity in clinical studies.
After stroke, recovery depends on restoring blood flow to penumbral tissue and promoting neuroplasticity. EECP improves cerebral perfusion and has shown improvements in neurological function scores.
Vascular tinnitus — the most common form — is caused by turbulent or impaired blood flow near the inner ear. EECP improves cochlear perfusion and has shown reductions in tinnitus severity.
EECP improves metabolic function by enhancing mitochondrial efficiency, improving insulin sensitivity, and increasing the vascular capacity needed for sustained physical activity.